OSLO, Norway, April 7, 2026 - Lytix Biopharma AS ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced the appointment of Renée Christine Amundsen as Chief Operating Officer (COO), effective immediately. Her appointment comes at a pivotal point as the Company continues to advance its clinical pipeline and sharpen its operational focus for the next stage of growth.

Amundsen brings more than 20 years of global leadership experience across the pharmaceutical and life sciences industries. She has led teams and operations through periods of scale and complexity, with a focus on translating strategy into execution within innovation-driven healthcare companies.

"We are entering an important phase for Lytix as we continue advancing our clinical programs and building the capabilities required to deliver long-term value," said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. "Renée brings strong execution capabilities that will enhance operational performance and support the company's continued growth."

As Chief Operating Officer, Amundsen will lead global operations, focusing on preparing the Company for late-stage development and ensuring disciplined execution across its clinical programs, including ruxotemitide and LTX-401, while maintaining alignment across functions, timelines, and cost.

Prior to joining Lytix, Amundsen served as Corporate Vice President at Novo Nordisk and held senior leadership roles at Merck KGaA, where she led large-scale commercial and operational initiatives and managed full P&L responsibility across multiple markets.

"I'm very pleased to be joining Lytix at such a meaningful point in its development," said Amundsen. "The company has built a strong foundation, and I look forward to working with the team to support continued clinical progress and ensure we are well positioned for the opportunities ahead."

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit www.lytixbiopharma.com